Prognostic Outcomes of Cutaneous Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Retrospective Comparative Cohort Study

Introduction: Cutaneous squamous cell carcinoma (cSCC) is the second most common cutaneous neoplasm, and its incidence is on the rise. While most cSCCs have an excellent prognosis, certain risk factors, especially immunosuppression, have been associated with higher rates of local recurrence (LR), metastasis, and poor prognosis. This study aims to assess the risk factors for LR and metastasis development in cSCC among solid organ transplant recipients (SOTRs) and compare these rates with those in immunocompetent patients. Materials and Methods: A retrospective observational study included cSCC cases from the University Hospital Reina Sofía in Córdoba, Spain, between 2002 and 2019. Demographic, clinical, and histopathological data were collected. Local recurrence and metastasis rates were analyzed, along with progression-free survival. Univariate analyses were performed to identify prognostic factors in SOTRs. Results: Among 849 cSCC cases, we found higher rates of local recurrence and metastasis in tumors developed by SOTRs compared to those in immunocompetent individuals. However, no significant differences in local recurrence, metastasis, or progression-free survival were observed between the two groups. Risk factors for adverse outcomes in SOTRs included tumor size > 2 cm, depth > 4 mm, and a higher Clark level. A total of 34.4% of SOTRs developed a second primary cSCC during the follow-up. Conclusions: In our study, cSCCs in SOTRs did not exhibit statistically significant differences in the rates of adverse outcomes compared to immunocompetent patients. The prognosis of cSCCs in SOTRs may be more related to other tumor-dependent risk factors than to the immunosuppression status itself. Future studies are needed to refine risk stratification and follow-up protocols to ensure the optimal management of high-risk cSCC cases, particularly among immunosuppressed patients.

[1]  Martin A. Weinstock,et al.  Oral Nicotinamide for Actinic Keratosis Prevention in Kidney Transplant Recipients: A Pilot Double-Blind, Randomized, Placebo-Controlled Trial. , 2023, Transplantation proceedings.

[2]  C. Linkous,et al.  Analysis of Metformin, Niacinamide, and Niacin as Skin Cancer Preventative Medications in Solid Organ Transplant Recipients. , 2023, Journal of American Academy of Dermatology.

[3]  K. Boberg,et al.  Rates of Second Tumor, Metastasis, and Death From Cutaneous Squamous Cell Carcinoma in Patients With and Without Transplant-Associated Immunosuppression. , 2023, JAMA dermatology.

[4]  D. Damian,et al.  Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. Reply. , 2023, New England Journal of Medicine.

[5]  Andrew J. Martin,et al.  Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. , 2023, The New England journal of medicine.

[6]  T. Shpitzer,et al.  Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients—A Comparison between Different Immunomodulating Conditions , 2023, Cancers.

[7]  J. Carucci,et al.  Association of Patient Risk Factors, Tumor Characteristics, and Treatment Modality With Poor Outcomes in Primary Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-analysis. , 2022, JAMA dermatology.

[8]  J. Carucci,et al.  Immunosuppressed patients are at increased risk of local recurrence, metastasis, and disease specific death from cutaneous squamous cell carcinoma , 2022, Archives of Dermatological Research.

[9]  C. Schmults,et al.  Immune status does not independently influence cutaneous squamous cell carcinoma metastasis and death when stratified by tumor stage: A dual center retrospective cohort analysis of primary N0 disease. , 2022, Journal of American Academy of Dermatology.

[10]  Danny J. Sharon,et al.  Clinical outcomes of high-risk cutaneous squamous cell carcinomas treated with Mohs micrographic surgery alone: an analysis of local recurrence, regional nodal metastases, progression-free survival, and disease-specific death. , 2022, Journal of American Academy of Dermatology.

[11]  S. Vogrin,et al.  A long‐term cohort study of acitretin for prevention of keratinocyte carcinoma in solid organ transplant recipients , 2022, The Australasian journal of dermatology.

[12]  H. Soyer,et al.  Chemoprevention of cutaneous squamous cell carcinoma and its precursors in solid organ transplant recipients using topical sirolimus: a randomized, double-blind, placebo-controlled pilot trial. , 2022, Journal of American Academy of Dermatology.

[13]  Joel L Cohen,et al.  Risk factors and prevention strategies for cutaneous squamous cell carcinoma in transplant recipients , 2022, International journal of dermatology.

[14]  M. Louwman,et al.  Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: a nationwide cancer registry study. , 2021, Journal of the American Academy of Dermatology.

[15]  Matthew C. Fox,et al.  Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Delphi Consensus Statement. , 2021, JAMA dermatology.

[16]  L. Herrinton,et al.  Cohort and Nested Case-Control Study of Cutaneous Squamous Cell Carcinoma in Solid Organ Transplant Recipients, by Medication. , 2021, Journal of the American Academy of Dermatology.

[17]  R. Pampena,et al.  Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: a systematic review of the literature , 2021, International journal of dermatology.

[18]  K. Khosrotehrani,et al.  Keratinocyte Cancer Mortality in Kidney Transplant Recipients , 2021, Transplantation.

[19]  R. Nijhawan,et al.  Factors Predicting Outcomes of Patients with High-Risk Squamous Cell Carcinoma Treated with Mohs Micrographic Surgery. , 2021, Journal of the American Academy of Dermatology.

[20]  R. Sultana,et al.  Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses. , 2020, Journal of the American Academy of Dermatology.

[21]  I. Zalaudek,et al.  European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. , 2020, European journal of cancer.

[22]  P. Mosca,et al.  Type of Organ Transplanted Impacts the Risk and Presentation of Cutaneous Squamous Cell Carcinoma in Transplant Recipients. , 2020, Experimental and Clinical Transplantation.

[23]  D. Brodland,et al.  Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs surgery: a five-year, multicenter, prospective cohort study. , 2020, Journal of the American Academy of Dermatology.

[24]  J. Bouwes Bavinck,et al.  Cutaneous squamous cell carcinoma (cSCC) and immunosurveillance – the impact of immunosuppression on frequency of cSCC , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  P. Morris,et al.  Declining incidence of keratinocyte carcinoma in organ transplant recipients , 2019, The British journal of dermatology.

[26]  T. Phillips,et al.  Pathological margins and advanced cutaneous squamous cell carcinoma of the head and neck , 2019, Journal of Otolaryngology - Head & Neck Surgery.

[27]  P. Austin,et al.  Incidence and Risk Factors of Keratinocyte Carcinoma After First Solid Organ Transplant in Ontario, Canada. , 2019, JAMA dermatology.

[28]  C. Schmults,et al.  Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women's Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. , 2019, JAMA dermatology.

[29]  O. Dekkers,et al.  Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? a systematic review and meta‐analysis , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[30]  W. Powlis,et al.  Outcomes following radiation for cutaneous squamous cell carcinoma of the head and neck: Associations between immune suppression and recurrence , 2019, Head & neck.

[31]  J. Bouwes Bavinck,et al.  Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients , 2019, JAMA dermatology.

[32]  S. Arron,et al.  Keratinocyte Carcinomas: Current Concepts and Future Research Priorities , 2018, Clinical Cancer Research.

[33]  E. Decullier,et al.  Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Bouwes Bavinck,et al.  Metastasis Risk of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients and Immunocompetent Patients. , 2018, Acta Dermato-Venereologica.

[35]  C. Schmults,et al.  Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. , 2018, Journal of the American Academy of Dermatology.

[36]  A. Mittal,et al.  Skin Cancers in Organ Transplant Recipients , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  C. Reddy,et al.  A multi‐institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck , 2017, Cancer.

[38]  Steven He,et al.  Trends of skin cancer mortality after transplantation in the United States: 1987 to 2013. , 2016, Journal of the American Academy of Dermatology.

[39]  C. Schmults,et al.  Outcomes of Patients With Multiple Cutaneous Squamous Cell Carcinomas: A 10-Year Single-Institution Cohort Study. , 2015, JAMA dermatology.

[40]  P. Nelemans,et al.  Clinical and histological prognostic factors for local recurrence and metastasis of cutaneous squamous cell carcinoma: analysis of a defined population. , 2013, Acta dermato-venereologica.

[41]  Jiali Han,et al.  Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. , 2013, Journal of the American Academy of Dermatology.

[42]  A. Qureshi,et al.  Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. , 2013, JAMA dermatology.

[43]  Amelia K Hausauer,et al.  Recurrence after treatment of cutaneous basal cell and squamous cell carcinomas in patients infected with human immunodeficiency virus. , 2013, JAMA dermatology.

[44]  E. Decullier,et al.  Sirolimus and secondary skin-cancer prevention in kidney transplantation. , 2012, The New England journal of medicine.

[45]  J. Leonardi-Bee,et al.  A systematic review of worldwide incidence of nonmelanoma skin cancer , 2012, The British journal of dermatology.

[46]  C. Mourouzis,et al.  Cutaneous head and neck SCCs and risk of nodal metastasis - UK experience. , 2009, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[47]  B. Schönfisch,et al.  Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. , 2008, The Lancet. Oncology.

[48]  Jean Kanitakis,et al.  Skin cancers after organ transplantation. , 2003, The New England journal of medicine.

[49]  C. Ko,et al.  Cutaneous Squamous Cell Carcinomas in Solid Organ Transplant Recipients Compared With Immunocompetent Patients , 2018, JAMA dermatology.